# NP28673 (NCT01801111)

> A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment

No report yet. It can be ordered.

- Drugs tested: alectinib
- Indication: crizotinib-resistant ALK-positive non-small cell lung cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01801111
- Phase: PHASE1, PHASE2
- Status: COMPLETED
- Sponsor: Hoffmann-La Roche
- Conditions: Non-Small-Cell Lung Carcinoma
- Interventions: Erlotinib; Alectinib
- Enrollment: 138
- Primary outcome: Recommended Phase 2 Dose (RP2D) of Alectinib
- Primary outcome: Percentage of Participants With Dose Limiting Toxicities (DLTs)
- Primary outcome: Percentage of Participants Achieving Objective Response (Complete Response [CR] or Partial Response [PR]) as Assessed by Independent Radiological Review Committee (IRC) in Response Evaluable (RE) Population
- Primary outcome: Percentage of Participants Achieving Objective Response (CR or PR) as Assessed by IRC in Chemotherapy-Pretreated Participants

## Indexed commentary on NP28673 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 4 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=np28673-nct01801111